PTCT PTC Therapeutics, Inc. - Common Stock
$72,62
Prezzo · Ago 19, 2026
Fondamentali al Lug 30, 2026
Intervallo 52 sett.
$48–$91
57% of range
Rating Analisti
BUY
21 analysts
Prezzo Obiettivo
$98
+35% upside
P/E (TTM)
9.3
ROE
-331.5%
Margine di Profitto Netto
39.4%
Informazioni su PTC Therapeutics, Inc. - Common Stock Panoramica della società da Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Leggi di più
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
PTCT Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$72.62
Capitalizzazione di Mercato
$5.92B
P/E (TTM)
9.3
EPS (TTM)
$7.78
Ricavi (TTM)
$1.73B
Rendimento div.
—
ROE
-331.5%
D/E Debito/Patrimonio
-1.4
Intervallo 52 sett.
$48 – $91
PTCT Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$1.73B
2016-12-31
→
2025-12-31
EPS
$7.78
2019-12-31
→
2025-12-31
Flusso di cassa libero
$702M
2016-12-31
→
2025-12-31
Margini
39.4%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
PTCT
Mediana dei peer
P/E (TTM)
9.3
37.2
P/S (TTM)
3.4
9.9
P/B
-28.8
8.3
EV / EBITDA
4.7
—
Price / FCF (Prezzo / FCF)
8.4
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
PTCT
Mediana dei peer
Operating Margin (Margine Operativo)
50.1%
—
Net Profit Margin (Margine di Profitto Netto)
39.4%
-15.1%
ROA
29.7%
-23.3%
ROE
-331.5%
-30.6%
ROIC
1044.7%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
PTCT
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
-1.4
—
Current Ratio (Rapporto corrente)
2.3
6.3
Quick Ratio
2.2
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
PTCT
Mediana dei peer
Revenue YoY (Ricavi YoY)
114.5%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
35.3%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
35.4%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
PTCT
Mediana dei peer
PTCT Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
21 analisti
- Acquisto forte 6 28,6%
- Compra 11 52,4%
- Mantieni 3 14,3%
- Vendi 1 4,8%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
14 analisti · 2026-08-13
Mediana
$98.00
Ora
$72.62
Basso
$70.00
Alto
$130.00
Target mediano
$98.00
+34,9%
Target medio
$97.86
+34,8%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
1.9%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.92 | $0.43 | 0.49% |
| 31 Marzo 2026 | $-0.03 | $-0.48 | 0.45% |
| 31 Dicembre 2025 | $-1.67 | $0.04 | -1.7% |
| 30 Settembre 2025 | $0.20 | $-1.40 | 1.6% |
| 30 Giugno 2025 | $-0.83 | $-1.08 | 0.25% |
| 31 Marzo 2025 | $10.04 | $-0.22 | 10.3% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | — |
| COGT | $5.72B | -16.4 | — | — | -83.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| PBLS | — | — | — | — | — | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 15
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 13
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Conto Economico 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | -155,203,905 | 78,471,119 | 78,151,240 | 78,115,836 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | -163,341,037 | 87,115,369 | 78,151,240 | 86,385,922 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Stato Patrimoniale 27
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Flusso di cassa 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efficienza 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Valutazione (TTM) 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.02B | $1.84B | · | $1.76B | $1.74B | $1.77B | · | $790M | $807M | $841M | · | $848M | $817M | $752M | · | $670M | |
| Net Income TTM | $32M | $815M | · | $711M | $596M | $569M | · | $-430M | $-523M | $-562M | · | $-580M | $-599M | $-527M | · | $-522M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | 313.7 | 7.3 | · | 7.7 | 7.5 | 8.3 | · | -6.6 | -4.4 | -3.9 | · | -2.9 | -5.0 | -6.6 | · | -6.8 | |
| P/S | 6.6 | 3.1 | · | 2.8 | 2.2 | 2.3 | · | 3.6 | 2.9 | 2.7 | · | 2.0 | 3.8 | 4.8 | · | 5.4 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| P / FCF | · | -93.7 | · | · | · | 4.6 | · | · | · | 36.5 | · | · | · | -90.2 | · | · | |
| EV / EBITDA | 34.6 | 66.9 | · | 1161.8 | -62.2 | 2.3 | · | -39.0 | -38.4 | 163.9 | · | -16.7 | -15.7 | -51.8 | · | -52.8 | |
| EV / FCF | · | -67.1 | · | · | · | 2.6 | · | · | · | 26.6 | · | · | · | -97.4 | · | · | |
| EV / Revenue | 5.0 | 2.2 | · | 2.0 | 1.3 | 1.3 | · | 2.7 | 1.9 | 1.9 | · | 2.3 | 4.0 | 5.1 | · | 5.4 | |
| Earnings Yield | 0.32% | 13.8% | · | 13.1% | 13.4% | 12.1% | · | -15.2% | -22.6% | -25.8% | · | -34.9% | -20.2% | -15.1% | · | -14.6% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $1.73B | $807M | $938M | $699M | $539M |
| Margine Operativo % | 50.1% | -37.5% | -46.9% | — | -69.5% |
| Utile netto | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Diluito | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | -1.4 | -0.3 | -0.3 | — | 300.0 |
| Rapporto corrente | 2.3 | 2.4 | 2.0 | — | 1.9 |
| Quick Ratio | 2.2 | 2.2 | 1.7 | — | 1.7 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $702M | $-114M | $-187M | — | $-280M |
Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 403 filer · $5.4B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 83 (+22 vs trimestre precedente) | 43 (-9 vs trimestre precedente) | 133 (-4 vs trimestre precedente) | 109 (+6 vs trimestre precedente) | +2.1M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 11,70% | Azioni |
| JANUS HENDERSON GROUP PLC | $479.178.655 | 7.034.622 | 8,87% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 7,45% | Azioni |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 6,95% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 5,65% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $292.435.873 | 3.585.091 | 5,42% | Azioni |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 2,96% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $155.132.041 | 1.901.417 | 2,87% | Azioni |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 2,63% | Azioni |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 2,60% | Azioni |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 2,27% | Azioni |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 2,18% | Azioni |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 2,05% | Azioni |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,75% | Azioni |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,73% | Azioni |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,62% | Azioni |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 1,59% | Azioni |
| D. E. Shaw & Co., Inc. | $77.478.857 | 949.845 | 1,44% | Azioni |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 1,39% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 1,19% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 1,09% | Azioni |
| Boston Partners | $57.080.953 | 699.871 | 1,06% | Azioni |
| FMR LLC | $56.956.987 | 698.259 | 1,05% | Azioni |
| BANK OF AMERICA CORP /DE/ | $56.350.840 | 690.828 | 1,04% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,99% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $51.486.821 | 631.199 | 0,95% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,89% | Azioni |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,77% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,76% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,67% | Azioni |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,66% | Azioni |
| LOOMIS SAYLES & CO L P | $35.387.921 | 433.835 | 0,66% | Azioni |
| Defilade Capital Management, L.P. | $35.376.827 | 433.699 | 0,66% | Azioni |
| GOLDMAN SACHS GROUP INC | $34.153.522 | 418.702 | 0,63% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.274.149 | 395.662 | 0,60% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $30.892.190 | 378.720 | 0,57% | Azioni |
| Qube Research & Technologies Ltd | $25.398.777 | 311.374 | 0,47% | Azioni |
| ARMISTICE CAPITAL, LLC | $24.471.000 | 300.000 | 0,45% | Opzione Call |
| Public Sector Pension Investment Board | $23.249.326 | 285.023 | 0,43% | Azioni |
| SEGALL BRYANT & HAMILL, LLC | $22.165.424 | 271.735 | 0,41% | Azioni |
| CITADEL ADVISORS LLC | $20.338.011 | 249.332 | 0,38% | Azioni |
| MORGAN STANLEY | $18.990.210 | 232.808 | 0,35% | Azioni |
| Boxer Capital Management, LLC | $16.314.000 | 200.000 | 0,30% | Azioni |
| RHUMBLINE ADVISERS | $15.718.994 | 192.706 | 0,29% | Azioni |
| AMERIPRISE FINANCIAL INC | $13.904.178 | 170.457 | 0,26% | Azioni |
| PRUDENTIAL FINANCIAL INC | $13.746.176 | 168.520 | 0,25% | Azioni |
| BlackRock, Inc. | $13.589.562 | 166.600 | 0,25% | Azioni |
| Rock Springs Capital Management LP | $13.238.648 | 162.298 | 0,25% | Azioni |
| Hudson Bay Capital Management LP | $13.033.091 | 159.778 | 0,24% | Azioni |
| Russell Investments Group, Ltd. | $12.687.724 | 155.544 | 0,23% | Azioni |
| Schonfeld Strategic Advisors LLC | $12.025.457 | 147.425 | 0,22% | Azioni |
| MARSHALL WACE, LLP | $11.724.301 | 143.733 | 0,22% | Azioni |
| Swiss National Bank | $11.539.300 | 141.465 | 0,21% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11.063.583 | 135.633 | 0,20% | Azioni |
| Legal & General Group Plc | $10.362.979 | 127.044 | 0,19% | Azioni |
| CITIGROUP INC | $9.272.143 | 113.671 | 0,17% | Azioni |
| FIRST TRUST ADVISORS LP | $9.246.285 | 113.354 | 0,17% | Azioni |
| Longaeva Partners L.P. | $9.119.771 | 111.803 | 0,17% | Azioni |
| JUPITER ASSET MANAGEMENT LTD | $8.927.184 | 109.442 | 0,17% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $8.215.404 | 100.716 | 0,15% | Azioni |
| SECTOR GAMMA AS | $8.157.000 | 100.000 | 0,15% | Azioni |
| WCM INVESTMENT MANAGEMENT, LLC | $7.651.184 | 93.799 | 0,14% | Azioni |
| PANAGORA ASSET MANAGEMENT INC | $7.256.141 | 88.956 | 0,13% | Azioni |
| VOYA INVESTMENT MANAGEMENT LLC | $7.239.501 | 88.752 | 0,13% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $7.217.488 | 105.937 | 0,13% | Azioni |
| Aquatic Capital Management LLC | $6.808.648 | 83.470 | 0,13% | Azioni |
| XTX Topco Ltd | $6.682.459 | 81.923 | 0,12% | Azioni |
| MOORE CAPITAL MANAGEMENT, LP | $6.165.713 | 75.588 | 0,11% | Azioni |
| PINNACLE ASSOCIATES LTD | $5.745.383 | 70.435 | 0,11% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $5.744.722 | 84.320 | 0,11% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $5.614.300 | 68.828 | 0,10% | Azioni |
| Capricorn Fund Managers Ltd | $5.212.323 | 63.900 | 0,10% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.000.241 | 61.300 | 0,09% | Opzione Call |
| INTECH INVESTMENT MANAGEMENT LLC | $4.696.882 | 57.581 | 0,09% | Azioni |
| ExodusPoint Capital Management, LP | $4.672.166 | 57.278 | 0,09% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $4.561.884 | 55.926 | 0,08% | Azioni |
| BARCLAYS PLC | $4.169.858 | 51.120 | 0,08% | Azioni |
| ORBIMED ADVISORS LLC | $4.005.087 | 49.100 | 0,07% | Azioni |
| MetLife Investment Management, LLC | $3.932.653 | 48.212 | 0,07% | Azioni |
| Point72 Europe (London) LLP | $3.829.919 | 62.407 | 0,07% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $3.792.516 | 46.494 | 0,07% | Azioni |
| Phocas Financial Corp. | $3.766.087 | 46.170 | 0,07% | Azioni |
| MARTINGALE ASSET MANAGEMENT L P | $3.627.826 | 44.475 | 0,07% | Azioni |
| Quadrature Capital Ltd | $3.589.488 | 44.005 | 0,07% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.531.981 | 43.300 | 0,07% | Opzione Put |
| STATE OF WISCONSIN INVESTMENT BOARD | $3.436.299 | 42.127 | 0,06% | Azioni |
| CREDIT AGRICOLE S A | $3.344.370 | 41.000 | 0,06% | Azioni |
| Fisher Asset Management, LLC | $3.322.345 | 40.730 | 0,06% | Azioni |
| HSBC HOLDINGS PLC | $3.200.425 | 38.732 | 0,06% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $3.134.490 | 38.427 | 0,06% | Azioni |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3.114.179 | 38.178 | 0,06% | Azioni |
| CenterBook Partners LP | $3.082.938 | 37.795 | 0,06% | Azioni |
| Rafferty Asset Management, LLC | $3.069.805 | 37.634 | 0,06% | Azioni |
| FIFTH THIRD BANCORP | $3.044.843 | 37.328 | 0,06% | Azioni |
| BURNEY CO/ | $3.044.192 | 37.320 | 0,06% | Azioni |
| Vanguard Global Advisers, LLC | $3.033.180 | 37.185 | 0,06% | Azioni |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | $3.007.731 | 36.873 | 0,06% | Azioni |
| Louisiana State Employees Retirement System | $2.969.148 | 36.400 | 0,05% | Azioni |
| JANE STREET GROUP, LLC | $2.854.950 | 35.000 | 0,05% | Opzione Put |
| CASTLEARK MANAGEMENT LLC | $2.765.223 | 33.900 | 0,05% | Azioni |
Insider aziendali 33 insider · 13 dirigenti · 14 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Stuart Walter Peltz | Chief Executive Officer | 01 Febbraio 2022 S | 38.728 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 Luglio 2026 S | 83.986 | 0 | 1 | $-280.743 |
| Emily Luisa Hill | Chief Financial Officer | 01 Febbraio 2022 S | 37.169 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 09 Maggio 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 Gennaio 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 Febbraio 2020 M | 6.744 | 0 | 0 | $0 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 09 Luglio 2026 M | 60.299 | 0 | 20 | $-9.184.852 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 06 Luglio 2026 M | 105.272 | 0 | 12 | $-1.254.986 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 Giugno 2026 M | 70.199 | 0 | 1 | $-1.487.474 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 Giugno 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Mark Rothera | Chief Commercial Officer | 24 Maggio 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 03 Gennaio 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 04 Gennaio 2016 A | 3.239 | 0 | 0 | $0 |
| Hege Elisabeth Sollie-Zetlmayer | Direttore | 28 Luglio 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Direttore | 09 Luglio 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Stephanie Okey | Direttore | 07 Gennaio 2022 A | 4.163 | 0 | 0 | $0 |
| Emma Reeve | Direttore | 07 Gennaio 2022 A | 7.528 | 0 | 0 | $0 |
| Allan Steven Jacobson | Direttore | 07 Gennaio 2022 A | 8.348 | 0 | 0 | $0 |
| Dawn Svoronos | Direttore | 07 Gennaio 2022 A | 29.755 | 0 | 0 | $0 |
| Jerome B Zeldis | Direttore | 07 Gennaio 2022 A | 6.500 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Direttore | 03 Gennaio 2017 A | — | 0 | 0 | $0 |
| Adam Koppel | Direttore | 03 Gennaio 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Direttore | 03 Gennaio 2017 A | — | 0 | 0 | $0 |
| Richard Aldrich | Direttore | 08 Giugno 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Direttore | 16 Marzo 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Direttore | 25 Giugno 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Proprietario del 10% | 17 Dicembre 2013 S | 2.441.504 | 0 | 0 | $0 |
| Matthew B. Klein | — | 04 Agosto 2026 S | 383.868 | 0 | 1 | $-705.722 |
| Michael Schmertzler | — | 02 Gennaio 2026 A | 163.266 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | — | 02 Gennaio 2026 A | 22.500 | 0 | 1 | $-916.200 |
| David P Southwell | — | 02 Gennaio 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | — | 28 Aprile 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | — | 25 Giugno 2013 C | 2.256.882 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 3 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 depositi | 30 Gennaio 2015 | — | Deposito iniziale | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 depositi | 12 Novembre 2014 | — | Deposito iniziale | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 05 Luglio 2013 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 87 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,81% | 4.145 SH | 08 Agosto 2026 | Giornaliero |
| PSCH · Invesco Exchange-Traded Fund Trust … | 3,08% | 71.992 SH | 08 Agosto 2026 | Giornaliero |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 128.216 SH | 08 Agosto 2026 | Giornaliero |
| XSMO · Invesco Exchange-Traded Fund Trust | 1,52% | 642.023 SH | 08 Agosto 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,37% | 12.510 NS | 30 Aprile 2026 | N-PORT |
| SIXS · EXCHANGE TRADED CONCEPTS TRUST | 1,30% | 22.380 NS | 31 Maggio 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,25% | 23.662 SH | 08 Agosto 2026 | Giornaliero |
| GURU · Global X Funds | 1,03% | 9.268 NS | 30 Aprile 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 73.928 NS | 30 Aprile 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,83% | 10.625 NS | 30 Aprile 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 08 Agosto 2026 | Giornaliero |
| VMAX · Lattice Strategies Trust | 0,72% | 5.120 NS | 30 Aprile 2026 | N-PORT |
| IJT · iShares Trust | 0,66% | 770.376 SH | 08 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 40.257 NS | 30 Aprile 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,49% | 3.490 NS | 31 Maggio 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,49% | 40.488 NS | 31 Maggio 2026 | N-PORT |
| IBB · iShares Trust | 0,44% | 588.017 SH | 08 Agosto 2026 | Giornaliero |
| HQGO · Lattice Strategies Trust | 0,43% | 3.203 NS | 30 Aprile 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,41% | 4.514 SH | 08 Agosto 2026 | Giornaliero |
| OASC · Unified Series Trust | 0,40% | 4.569 NS | 31 Maggio 2026 | N-PORT |
| BRNY · EA Series Trust | 0,40% | 34.057 NS | 30 Aprile 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 08 Agosto 2026 | Giornaliero |
| XJR · iShares Trust | 0,37% | 9.802 SH | 08 Agosto 2026 | Giornaliero |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,34% | 35.034 NS | 31 Maggio 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 08 Agosto 2026 | Giornaliero |
| ESSC · Strategy Shares | 0,34% | 1.335 NS | 30 Aprile 2026 | N-PORT |
| IJR · iShares Trust | 0,32% | 5.058.562 SH | 08 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,31% | 641.280 SH | 08 Agosto 2026 | Giornaliero |
| BIB · ProShares Trust | 0,31% | 3.062 NS | 31 Maggio 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,31% | 11.451 NS | 31 Maggio 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,30% | 39.411 NS | 31 Maggio 2026 | N-PORT |
| SAA · ProShares Trust | 0,26% | 961 NS | 31 Maggio 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 22.443 NS | 30 Aprile 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 27.276 NS | 30 Aprile 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,23% | 2.877 NS | 30 Aprile 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,23% | 3.003 NS | 31 Maggio 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 08 Agosto 2026 | Giornaliero |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,20% | 39.967 NS | 30 Aprile 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 08 Agosto 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,18% | 72.691 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,18% | 2.102.256 SH | 08 Agosto 2026 | Giornaliero |
| LRGF · iShares Trust | 0,16% | 84.151 SH | 08 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,16% | 22.792 SH | 08 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,16% | 34.125 NS | 30 Aprile 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.071 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,15% | 3.710 NS | 31 Maggio 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 08 Agosto 2026 | Giornaliero |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 49.932 NS | 30 Aprile 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,14% | 5.350 SH | 08 Agosto 2026 | Giornaliero |
| SMDX · Tidal Trust III | 0,13% | 2.579 NS | 30 Aprile 2026 | N-PORT |